

Model Peptides Reveal Specificity of N^{α} -Acetyltransferase from *Saccharomyces cerevisiae**

(Received for publication, January 12, 1990)

Fang-Jen S. Lee‡§, Lee-Wen Lin‡§, and John A. Smith‡¶||

From the Departments of ‡Molecular Biology and ¶Pathology, Massachusetts General Hospital, and the Departments of §Genetics and ||Pathology, Harvard Medical School, Boston, Massachusetts 02114

***N*^α-Acetylation is a major co-translational modification occurring at the α-NH₂ group of eukaryotic cytosolic proteins. In order to understand better the specificity of *N*^α-acetyltransferase, we used the purified enzyme from yeast (Lee, F.-J. S., Lin, L.-W., and Smith J. A. (1988) *J. Biol. Chem.* 263, 14948–14955) and synthetic peptides mimicking the NH₂ terminus of yeast and human proteins. Alcohol dehydrogenase I-(1–24) and 8 of the 19 synthetic analogues with substitutions at the NH₂-terminal residue were *N*^α-acetylated with varying efficiency. Penultimate amino acid substitutions, except for proline, had little influence on *N*^α-acetylation. Substitution of sequences from *N*^α-acetylated proteins into the yeast sequences which cannot be *N*^α-acetylated demonstrated that not only the first 3 NH₂-terminal residues but also more carboxyl-terminal residues were important for determining the specificity of *N*^α-acetyltransferase. Two other peptides mimicking yeast mitochondrial cytochrome *c* oxidase (subunit VI) and ATPase inhibitor, which are naturally non-acetylated, were efficiently acetylated. In addition, recombinant human alcohol dehydrogenase I and basic fibroblast growth factor, which are naturally *N*^α-acetylated, were not acetylated post-translationally.**

EXPERIMENTAL PROCEDURES

Materials—Purified, recombinant proteins, human basic fibroblast growth factor (FGF), and human ADH I, expressed in yeast and *Escherichia coli*, respectively, were gifts from Dr. L. S. Cousens (Chiron Corporation) and from Professor Hans Jornvall (Karolinska Institute), respectively. The recombinant, human basic FGF consisted of a nearly equal mixture of the N^{α} -acetylated and non-acetylated forms of human basic FGF (Barr *et al.*, 1988). [^3H]Acetyl-CoA was from Amersham Corp., and unlabeled acetyl-CoA was from P-L Biochemicals. SP membrane was from Cuno Inc. Reagents for protein synthesis were from Applied Biosystems, except *t*-butoxycarbonyl amino acids were from Peninsula and solvents were from Anachem. Reagents and solvents for amino acid analysis and Ready-Solv EP scintillation mixture were from Beckman. Reagents for protein sequence analysis were from Applied Biosystems. All other chemicals were reagent grade or better.

Peptide Synthesis—Peptides were synthesized using the *t*-butoxycarbonyl chemistry and an Applied Biosystems 430A Peptide Synthesizer and characterized as described previously (Finnegan *et al.*, 1986). Protein sequence analyses of the ADH I-(1–24) peptide analogues were carried out using an Applied Biosystems 470A Protein Sequencer (Hewick *et al.*, 1981).

Purification of Yeast N^{α} -Acetyltransferase and N^{α} -Acetylation Assays—The purification of yeast N^{α} -acetyltransferase and the enzyme assays utilizing the various synthetic peptide and recombinant protein substrates were performed as described previously (Lee *et al.*, 1988). The data were reported as percent activity compared with the level of acetylation of a synthetic human adrenocorticotrophic hormone peptide (ACTH), ACTH-(1–24), used previously as a control peptide for assaying for N^{α} -acetyltransferase (Woodford and Dixon, 1979).

TABLE I
Relative activity of yeast acetyltransferase for the N^{α} -acetylation of
ADH I-(1-24) and substituted analogues

Substrate		Activity ^a	
		%	
ACTH (human)		100 ± 5 (control)	
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp- Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg- Arg-Pro-Val-Lys-Val-Tyr-Pro			
Alcohol dehydrogenase I-(1-24) (yeast)		102 ± 5	
Ser-Ile-Pro-Glu-Thr-Gln-Lys-Gly-Val- Ile-Phe-Tyr-Glu-Ser-His-Gly-Lys- Leu-Glu-Tyr-Lys-Asp-Ile-Pro			
First amino acid substitution		Second amino acid substitution	
Substrate	Activity	Substrate	Activity
	%		%
Ala - - - - -	0	- Ala - - - - -	148 ± 10
Arg - - - - -	0	- Arg - - - - -	102 ± 5
Asn - - - - -	0	- Asn - - - - -	116 ± 5
Asp - - - - -	0	- Asp - - - - -	150 ± 11
Cys - - - - -	0	- Cys - - - - -	123 ± 7
Gln - - - - -	0	- Gln - - - - -	125 ± 7
Glu - - - - -	0	- Glu - - - - -	111 ± 6
Gly - - - - -	23 ± 4	- Gly - - - - -	84 ± 5
His - - - - -	19 ± 3	- His - - - - -	119 ± 6
Ile - - - - -	0	- Leu - - - - -	117 ± 7
Leu - - - - -	0	- Lys - - - - -	113 ± 8
Lys - - - - -	0	- Met - - - - -	120 ± 7
Met - - - - -	15 ± 3	- Phe - - - - -	110 ± 6
Phe - - - - -	9 ± 3	- Pro - - - - -	0
Pro - - - - -	70 ± 5	- Ser - - - - -	122 ± 7
Thr - - - - -	103 ± 6	- Thr - - - - -	128 ± 8
Trp - - - - -	0	- Trp - - - - -	81 ± 5
Tyr - - - - -	20 ± 3	- Tyr - - - - -	129 ± 8
Val - - - - -	69 ± 4	- Val - - - - -	110 ± 7

^a Data reported as mean activity ± S.D. ($n = 3-5$).

TABLE II
Relative activity of yeast acetyltransferase for the N^α-acetylation of superoxide dismutase, enolase, and various
chimeric synthetic peptides

Substrate	Activity ^a
	%
ACTH-(1-24) Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg- Pro-Val-Lys-Val-Tyr-Pro	100 ± 5 (control)
Superoxide dismutase-(1-24) (human) Ala-Thr-Lys-Ala-Val-Cys-Val-Leu-Lys-Gly-Asp-Gly-Pro-Val-Gln-Gly-Ser-Ile-Asn- Phe-Glu-Gln-Lys-Glu	86 ± 6
Superoxide dismutase-(1-24) (yeast) Val-Gln-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys-Phe- Glu-Gln-Ala-Ser-Glu	0
[Ala ⁻¹ ,Thr ¹]Superoxide dismutase-(1-24) (yeast) Ala-Thr-Gln-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- Phe-Glu-Gln-Ala-Ser	14 ± 4
[Ala ⁻¹ ,Thr ¹ ,Lys ²]Superoxide dismutase-(1-24) (yeast) Ala-Thr-Lys-Ala-Val-Ala-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- Phe-Glu-Gln-Ala-Ser	54 ± 5
[Ala ⁻¹ ,Thr ¹ ,Lys ² ,Ala ³ ,Val ⁴ ,Cys ⁵]Superoxide dismutase-(1-24) (yeast) Ala-Thr-Lys-Ala-Val-Cys-Val-Leu-Lys-Gly-Asp-Ala-Gly-Val-Ser-Gly-Val-Val-Lys- Phe-Glu-Gln-Ala-Ser	80 ± 5
Enolase-(1-24) (human) Ser-Ile-Leu-Lys-Ile-His-Ala-Arg-Glu-Ile-Phe-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- Glu-Val-Asp-Leu-Phe	54 ± 5
Enolase-(1-24) (yeast) Ala-Val-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- Glu-Val-Glu-Leu-Thr	0
[Ser ¹ ,Ile ²]Enolase-(1-24) (yeast) Ser-Ile-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- Glu-Val-Glu-Leu-Thr	60 ± 7
[Thr ² ,Lys ³]Enolase-(1-24) Ala-Thr-Lys-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr- Val-Glu-Val-Glu-Leu-Thr	20 ± 4
[Tyr ²]Enolase-(1-24) (yeast) Ala-Tyr-Ser-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- Glu-Val-Glu-Leu-Thr	0
[Ala ³]Enolase-(1-24) (yeast) Ala-Val-Ala-Lys-Val-Tyr-Ala-Arg-Ser-Val-Tyr-Asp-Ser-Arg-Gly-Asn-Pro-Thr-Val- Glu-Val-Glu-Leu-Thr	0

^a Data reported as mean activity ± S.D. (n = 3-5).

TABLE III

Relative activity of yeast acetyltransferase for the N^a-acetylation of synthetic peptides mimicking mitochondrial proteins

Substrate	Activity ^a
	%
ACTH-(1-24) Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro	100 ± 5 (control)
Cytochrome <i>c</i> oxidase-(1-24) (yeast, mitochondrial, subunit VI) Ser-Asp-Ala-His-Asp-Glu-Glu-Thr-Phe-Glu-Glu-Phe-Thr-Ala-Arg-Tyr-Glu-Lys-Glu-Phe-Asp-Glu-Ala-Tyr	60 ± 5
ATPase inhibitor (1-24) (yeast, mitochondrial) Ser-Glu-Gly-Ser-Thr-Gly-Thr-Pro-Arg-Gly-Ser-Gly-Ser-Glu-Asp-Ser-Phe-Val-Lys-Arg-Glu-Arg-Ala-Thr	76 ± 6

^a Data reported as mean activity ± S.D. (*n* = 3-5).

N^α-Acetylation of synthetic peptides, mutagenized model proteins, and naturally occurring proteins

Peptide/protein substrates for <i>N</i> ^α -acetyltransferases	<i>N</i> ^α -Acetylated amino acid residue																	Reference
	Ala	Arg	Asn	Asp	Cys	Gln	Glu	Gly	His	Ile	Leu	Lys	Met	Phe	Pro	Ser	Thr	
Yeast alcohol dehydrogenase I- (1-24) and its 19 NH ₂ -termi- nally substituted peptide ana- logues	(-) ^a	-	-	-	-	-	-	+	+	-	-	-	+	+	+	+	+	This work in Table I
Recombinant plant thaumatin and its 19 variants with NH ₂ - terminal substitution	+ ^c	-	-	-	+/-	-	-	+	-	-	-	-	+	-	-	+	+	Huang <i>et al.</i> (1987)
Human hemoglobin β-chain vari- ants	+	-	-	-	+	-	-	+	-	-	-	-	+	-	-	+	+	Boissel <i>et al.</i> (1988)
Various <i>N</i> ^α -acetylated proteins (118)	+	ND ^d	+	+	ND	ND	+	+	ND	ND	ND	ND	+	ND	ND	+	+	Driessen <i>et al.</i> (1985)
Various cytosolic, <i>N</i> ^α -acetylated eukaryotic proteins (71)	+	ND	ND	+	ND	ND	+	+	ND	ND	ND	ND	+	ND	+	+	+	Flinta <i>et al.</i> (1986)
Side-chain type ^e	Alk	+	NH ₂	-	SH	NH ₂	-		+		Alk	+	SCH ₃	Ar		OH	OH	
Maximum side-chain length (Å)	1.51	7.40	3.68	3.74	2.83	4.93	4.97	-	4.64	3.91	3.90	6.37	5.46	5.10	2.40	2.41	5.54	Hirel <i>et al.</i> (1989)
Radius of gyration (Å)	0.77	2.38	1.45	1.43	1.22	1.75	1.77	-	1.78	1.56	1.54	2.08	1.80	1.90	1.25	1.08	1.24	Levitt (1976)
Mean solvent-accessible surface area (Å ²)	31.5	93.8	62.2	60.9	13.9	74.0	72.3	25.2	46.7	23.0	29.0	110	30.5	28.7	53.7	44.2	46.0	Rose <i>et al.</i> (1985a)
N-end rule category ^f	S ^I	S ^I	S ^{III}	S ^{II}	S ^{II}	S ^{III}	S ^{II}	DS	S ^I	DS	S ^I	S ^I	DS	S ^I	DS	S ^I	S ^I	Gonda <i>et al.</i> (1989)

^a [Ala¹]ADH I-(1-24) was not acetylated by yeast *N*^α-acetyltransferase, although the purified enzyme is capable of *N*^α-acetylating the NH₂-terminal alanyl residue of human superoxide dismutase-(1-24) (see Table II) and of recombinant human superoxide dismutase protein (Hallewell *et al.*, 1987).

^b NH₂-terminal residue of yeast alcohol dehydrogenase I.

^c NH₂-terminal residue of recombinant thaumatin expressed in yeast.

^d ND, *N*^α-acetylated residue not detected in any protein of this data base.

^e Abbreviations: +, positively charged; -, negatively charged; Alk, alkyl; Ar, aromatic; OH, hydroxyl; SH, sulfhydryl; NH₂, amide; SCH₃, methylated thiol.

^f Abbreviations: S^x, stabilizing residues (x = I (primary), II (secondary), III (tertiary)); DS, destabilizing residues.